Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Urinary Bladder Neoplasms × Meropenem × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

Gemcitabine 136 Cisplatin 101 pembrolizumab 71 Cystectomy 42 Paclitaxel 39 Docetaxel 39 Carboplatin 37 Nivolumab 36 Mitomycin 34 durvalumab 30 atezolizumab 29 Radiotherapy 29 Magnetic Resonance Spectroscopy 28 avelumab 23 Specimen Handling 23 BCG Vaccine 23 Cystoscopy 22 Doxorubicin 20 Fluorouracil 18 enfortumab vedotin 16 Methotrexate 15 Vinblastine 14 Standard of Care 14 5-aminolevulinic acid hexyl ester 14 Ipilimumab 13 Filgrastim 13 vinflunine 12 Biopsy 12 tremelimumab 11 Transurethral Resection of Bladder 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05392634 2022-05-31

MACS

N.N. Petrov National Medical Research Center of Oncology

Phase 3 Unknown

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡